ReVessel Introduces AI-Driven Digital Twin of Human Blood for Personalized Medicine
ReVessel's development of a digital twin for human blood marks a significant advancement in personalized medicine, offering real-time, AI-powered simulations to enhance clinical decision-making.
ReVessel, a health-tech company, has unveiled the first digital twin of human blood, an AI-powered platform that simulates an individual's hematologic and hemodynamic state in real time. This innovation converts blood into a dynamic, encrypted data layer, facilitating personalized modeling and improving clinical decisions. Unlike conventional models, ReVessel's technology integrates multi-omics, pharmacokinetics, and clinical data to create tailored simulations, moving away from generic treatment approaches.
The platform's digital twin engine replicates blood dynamics interactively, predicting responses to various conditions or treatments within milliseconds. This capability allows healthcare providers to make quicker, more informed decisions at the point of care. Designed for easy integration, ReVessel supports standard clinical data formats like EMR, FHIR, and OMOP, enabling hospitals to adopt the technology without significant infrastructure changes.
Currently in early development, ReVessel is not yet available commercially. The company is working with clinical advisors and research institutions to refine and validate its platform, while also seeking investors and collaborators to further its mission of personalized blood management. For more details, visit https://myrevessel.com.